OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
OCULAR THERAPEUTIX, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$6.29−0.58 (-8.44%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
94.4%
207M of 220M shares
Institutional holders
262
34 new, 38 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
1 buys · 26 sales
Net sold $2.60M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 31,785,634 | 15.00% | 13G (passive) amendment | Sep 30, 2025 |
| Deep Track Capital, LP | 20,850,000 | 9.53% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 15,227,768 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| Nimish Shah | 12,913,420 | 7.30% | 13G (passive) amendment | Sep 30, 2025 |
| Behzad Aghazadeh | 12,714,874 | 7.90% | 13G (passive) | Sep 30, 2024 |
| Summer Road LLC | 12,134,357 | 5.70% | 13G (passive) | Dec 4, 2025 |
| Deep Track Biotechnology Master Fund, Ltd. | 11,234,132 | 5.13% | 13G (passive) | Feb 5, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OCUL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 32,844,043 | 14.96% | $322.53M | +190,279 | 0.01% |
| Deep Track Capital, LP | 19,686,282 | 8.96% | $193.32M | – | 2.81% |
| BlackRock, Inc. | 19,376,555 | 8.82% | $190.28M | +3,243,624 | 0.00% |
| Avoro Capital Advisors LLC | 12,540,000 | 5.71% | $123.14M | +225,000 | 1.11% |
| Summer Road LLC | 12,208,296 | 5.56% | $119.89M | +328,471 | 74.46% |
| VR Adviser, LLC | 10,346,926 | 4.71% | $101.61M | – | 3.08% |
| Vanguard Capital Management LLC | 8,832,595 | 4.02% | $86.74M | +113,556 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 7,623,533 | 3.47% | $74.86K | +1,726,384 | 0.01% |
| Logos Global Management LP | 5,300,000 | 2.41% | $52.05M | +1,450,000 | 2.24% |
| State Street Corp | 5,233,282 | 2.38% | $51.39M | +524,863 | 0.00% |
| Geode Capital Management, LLC | 5,021,092 | 2.29% | $49.32M | +491,907 | 0.00% |
| Point72 Asset Management, L.P. | 3,292,193 | 1.50% | $32.33M | −2,242,792 | 0.04% |
| Dimensional Fund Advisors LP | 2,783,367 | 1.27% | $27.33M | +2,133,611 | 0.00% |
| Deltec Asset Management LLC | 2,476,197 | 1.13% | $24.32M | +135,577 | 3.59% |
| Balyasny Asset Management L.P. | 2,270,707 | 1.03% | $22.30M | −421,915 | 0.03% |
| Octagon Capital Advisors LP | 2,075,000 | 0.94% | $20.38M | −1,091,600 | 1.83% |
| Vanguard Portfolio Management LLC | 1,973,130 | 0.90% | $19.38M | +378,464 | 0.00% |
| Northern Trust Corp | 1,799,426 | 0.82% | $17.67M | +273,800 | 0.00% |
| Goldman Sachs Group Inc | 1,761,754 | 0.80% | $17.30M | +651,388 | 0.00% |
| Nuveen, LLC | 1,697,274 | 0.77% | $16.67M | +1,286,194 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 262 | 207M | 94.4% | 34 / 107 | 79 / 38 | 23M | 22M |
| Q1 2026 | 271 | 207M | 94.3% | 79 / 104 | 59 / 51 | 65M | 38M |
| Q4 2025 | 249 | 192M | 87.2% | 59 / 103 | 61 / 20 | 32M | 28M |
| Q3 2025 | 216 | 188M | 85.8% | 51 / 71 | 59 / 18 | 45M | 14M |
| Q2 2025 | 186 | 157M | 71.7% | 24 / 75 | 48 / 31 | 28M | 9M |
| Q1 2025 | 196 | 138M | 62.7% | 35 / 60 | 57 / 16 | 14M | 9M |
| Q4 2024 | 179 | 134M | 60.9% | 31 / 63 | 36 / 17 | 6M | 12M |
| Q3 2024 | 168 | 140M | 63.8% | 35 / 41 | 49 / 17 | 24M | 16M |
| Q2 2024 | 151 | 144M | 65.7% | 39 / 57 | 26 / 35 | 32M | 14M |
| Q1 2024 | 147 | 126M | 57.5% | 47 / 58 | 24 / 17 | 58M | 6M |
| Q4 2023 | 118 | 75M | 34.0% | 26 / 39 | 29 / 21 | 38M | 4M |
| Q3 2023 | 113 | 40M | 18.4% | 8 / 45 | 29 / 30 | 3M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of OCUL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 9,716,358 | 4.42% | $87.54M | 0.09% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 6,616,995 | 3.01% | $64.98M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 5,284,839 | 2.41% | $51.90M | 0.06% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 2,688,679 | 1.22% | $24.22M | 0.09% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 2,611,078 | 1.19% | $23.53M | 0.10% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 2,252,224 | 1.03% | $18.40M | 0.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 2,003,277 | 0.91% | $19.67M | 0.02% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,789,197 | 0.81% | $17.57M | 0.12% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,570,555 | 0.72% | $15.42M | 0.10% | Jun 30, 2026 |
| Invesco Pharmaceuticals ETF | 1,489,689 | 0.68% | $12.17M | 2.58% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,484,000 | 0.68% | $14.57M | 0.15% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,432,466 | 0.65% | $14.07M | 0.12% | Jun 30, 2026 |
| Select Pharmaceuticals Portfolio | 1,331,717 | 0.61% | $12.00M | 0.80% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 965,858 | 0.44% | $8.70M | 0.05% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 902,797 | 0.41% | $8.13M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pravin Dugel | See Remarks, Director | 3,270,332 | 1.49% | Aug 26, 2026 |
| Donald Notman | Chief Operating Officer | 366,529 | 0.17% | Sep 2, 2026 |
| Peter Kaiser | Chief Development Officer | 264,378 | 0.12% | Aug 26, 2026 |
| Jeffrey S. Heier | Chief Scientific Officer | 318,326 | 0.14% | Aug 26, 2026 |
| Sanjay Nayak | Chief Strategy Officer | 326,898 | 0.15% | Aug 26, 2026 |
| Jason Shand Robins | Chief Financial Officer | 68,097 | 0.03% | Jun 12, 2026 |
| Nadia Waheed | Chief Medical Officer | 300,079 | 0.14% | Jun 5, 2026 |
| David Wayne Robinson | Global CCO | 136,000 | 0.06% | Jan 26, 2026 |
| Todd Anderman | Chief Legal Officer | 152,468 | 0.07% | Jan 6, 2026 |
| Namrata Saroj | Chief Business Officer | 254,620 | 0.12% | Jan 6, 2026 |
| Steve Lawrence Meyers | Chief Commercial Officer | 217,628 | 0.10% | Jan 6, 2026 |
| Richard L. Lindstrom Md | Director | 304,492 | 0.14% | Jun 12, 2026 |
| Merilee Raines | Director | 60,933 | 0.03% | Jun 12, 2026 |
| Charles M. Warden | Director | 100,464 | 0.05% | Jun 12, 2026 |
| Leslie J. Williams | Director | 65,433 | 0.03% | Jun 12, 2026 |
| Seung Suh Hong | Director | 60,933 | 0.03% | Jun 12, 2026 |
| Adrienne L. Graves | Director | 64,000 | 0.03% | Jun 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Donald Notman Chief Operating Officer | Aug 31, 2026 | Sale | −1,099 | $10.24 | $11.25K | 366,529 |
| Pravin Dugel See Remarks, Director | Aug 25, 2026 | Gift | −50,092 | – | – | 0 |
| Pravin Dugel See Remarks, Director | Aug 25, 2026 | Gift | +50,092 | – | – | 744,903 |
| Jeffrey S. Heier Chief Scientific Officer | Aug 24, 2026 | Sale(10b5-1 plan) | −3,296 | $10.78 | $35.53K | 318,326 |
| Pravin Dugel See Remarks, Director | Aug 24, 2026 | Sale(10b5-1 plan) | −21,649 | $10.77 | $233.16K | 2,525,429 |
| Peter Kaiser Chief Development Officer | Aug 24, 2026 | Sale(10b5-1 plan) | −3,035 | $10.77 | $32.69K | 264,378 |
| Sanjay Nayak Chief Strategy Officer | Aug 24, 2026 | Sale(10b5-1 plan) | −1,897 | $10.78 | $20.45K | 326,898 |
| Pravin Dugel See Remarks, Director | Jun 16, 2026 | Gift | −50,092 | – | – | 2,547,078 |
| Pravin Dugel See Remarks, Director | Jun 16, 2026 | Gift | +50,092 | – | – | 50,092 |
| Jason Shand Robins Chief Financial Officer | Jun 10, 2026 | Award | +15,441 | – | – | 68,097 |
| Merilee Raines Director | Jun 10, 2026 | Award | +14,000 | – | – | 60,933 |
| Charles M. Warden Director | Jun 10, 2026 | Award | +14,000 | – | – | 100,464 |
| Richard L. Lindstrom Md Director | Jun 10, 2026 | Award | +14,000 | – | – | 260,933 |
| Leslie J. Williams Director | Jun 10, 2026 | Award | +14,000 | – | – | 65,433 |
| Adrienne L. Graves Director | Jun 10, 2026 | Award | +14,000 | – | – | 64,000 |
| Seung Suh Hong Director | Jun 10, 2026 | Award | +14,000 | – | – | 60,933 |
| Nadia Waheed Chief Medical Officer | Jun 3, 2026 | Sale(10b5-1 plan) | −14,828 | $8.27 | $122.63K | 300,079 |
| Pravin Dugel See Remarks, Director | May 28, 2026 | Gift | +394,696 | – | – | 694,811 |
| Pravin Dugel See Remarks, Director | May 28, 2026 | Gift | −394,696 | – | – | 0 |
| Sanjay Nayak Chief Strategy Officer | May 26, 2026 | Sale(10b5-1 plan) | −1,858 | $8.20 | $15.24K | 328,795 |
| Pravin Dugel See Remarks, Director | May 26, 2026 | Sale(10b5-1 plan) | −21,156 | $8.20 | $173.48K | 2,597,170 |
| Jeffrey S. Heier Chief Scientific Officer | May 26, 2026 | Sale(10b5-1 plan) | −3,018 | $8.20 | $24.75K | 320,350 |
| Peter Kaiser Chief Development Officer | May 26, 2026 | Sale(10b5-1 plan) | −2,967 | $8.20 | $24.33K | 266,141 |
| Pravin Dugel See Remarks, Director | Apr 9, 2026 | Gift | −394,696 | – | – | 2,618,326 |
| Pravin Dugel See Remarks, Director | Apr 9, 2026 | Gift | +394,696 | – | – | 394,696 |
| Peter Kaiser Chief Development Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −2,810 | $8.28 | $23.27K | 269,108 |
| Sanjay Nayak Chief Strategy Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −1,759 | $8.28 | $14.56K | 330,653 |
| Pravin Dugel See Remarks, Director | Feb 23, 2026 | Sale(10b5-1 plan) | −20,056 | $8.28 | $166.06K | 3,013,022 |
| Jeffrey S. Heier Chief Scientific Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −3,057 | $8.28 | $25.31K | 323,368 |
| Nadia Waheed Chief Medical Officer | Feb 20, 2026 | Sale(10b5-1 plan) | −3,510 | $7.74 | $27.17K | 314,907 |
| Richard L. Lindstrom Md Director | Feb 20, 2026 | Buy | +60,229 | $7.66 | $461.35K | 246,933 |
| Donald Notman Chief Operating Officer | Feb 12, 2026 | Sale | −11,446 | $9.04 | $103.47K | 366,356 |
| Nadia Waheed Chief Medical Officer | Feb 12, 2026 | Sale(10b5-1 plan) | −7,863 | $9.04 | $71.08K | 318,417 |
| Sanjay Nayak Chief Strategy Officer | Feb 12, 2026 | Sale(10b5-1 plan) | −10,348 | $9.04 | $93.55K | 332,412 |
| Pravin Dugel See Remarks, Director | Feb 12, 2026 | Sale(10b5-1 plan) | −124,882 | $9.04 | $1.13M | 3,033,078 |
| Donald Notman Chief Operating Officer | Feb 4, 2026 | Sale | −6,035 | $8.54 | $51.54K | 377,802 |
| Donald Notman Chief Operating Officer | Feb 2, 2026 | Sale | −5,455 | $9.14 | $49.86K | 383,837 |
| David Wayne Robinson Global CCO | Jan 21, 2026 | Award | +136,000 | – | – | 136,000 |
| Namrata Saroj Chief Business Officer | Jan 2, 2026 | Award | +79,112 | – | – | 254,620 |
| Nadia Waheed Chief Medical Officer | Jan 2, 2026 | Award | +79,112 | – | – | 326,280 |
| Todd Anderman Chief Legal Officer | Jan 2, 2026 | Award | +64,900 | – | – | 152,468 |
| Jeffrey S. Heier Chief Scientific Officer | Jan 2, 2026 | Award | +79,112 | – | – | 326,425 |
| Peter Kaiser Chief Development Officer | Jan 2, 2026 | Award | +79,112 | – | – | 271,918 |
| Sanjay Nayak Chief Strategy Officer | Jan 2, 2026 | Award | +64,900 | – | – | 342,760 |
| Donald Notman See Remarks | Jan 2, 2026 | Award | +79,112 | – | – | 389,292 |
| Steve Lawrence Meyers Chief Commercial Officer | Jan 2, 2026 | Award | +64,900 | – | – | 217,628 |
| Pravin Dugel See Remarks, Director | Nov 26, 2025 | Gift | −49,754 | – | – | 0 |
| Pravin Dugel See Remarks, Director | Nov 26, 2025 | Gift | +49,754 | – | – | 300,115 |
| Sanjay Nayak Chief Strategy Officer | Nov 24, 2025 | Sale(10b5-1 plan) | −1,878 | $12.04 | $22.61K | 277,860 |
| Jeffrey S. Heier Chief Scientific Officer | Nov 24, 2025 | Sale(10b5-1 plan) | −3,469 | $12.04 | $41.77K | 245,940 |
| Pravin Dugel See Remarks, Director | Nov 24, 2025 | Sale(10b5-1 plan) | −19,530 | $12.04 | $235.14K | 3,157,960 |
| Peter Kaiser Chief Development Officer | Nov 24, 2025 | Sale(10b5-1 plan) | −3,007 | $12.02 | $36.14K | 191,433 |
| Namrata Saroj Chief Business Officer | Nov 5, 2025 | Sale(10b5-1 plan) | −25,865 | $10.74 | $277.79K | 174,135 |
| Todd Anderman Chief Legal Officer | Oct 8, 2025 | Sale(10b5-1 plan) | −11,132 | $12.34 | $137.37K | 87,568 |
| Jeffrey S. Heier Chief Scientific Officer | Oct 2, 2025 | Sale(10b5-1 plan) | −10,502 | $11.04 | $115.94K | 249,409 |
| Peter Kaiser Chief Development Officer | Oct 2, 2025 | Sale(10b5-1 plan) | −9,653 | $11.03 | $106.47K | 194,440 |
| Pravin Dugel See Remarks, Director | Sep 9, 2025 | Gift | +49,754 | – | – | 49,754 |
| Pravin Dugel See Remarks, Director | Sep 9, 2025 | Gift | −49,754 | – | – | 3,177,490 |
| Donald Notman See Remarks | Sep 2, 2025 | Sale | −1,066 | $12.43 | $13.25K | 308,807 |
| Pravin Dugel See Remarks, Director | Aug 25, 2025 | Sale(10b5-1 plan) | −21,494 | $12.04 | $258.79K | 3,227,244 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Anderman Todd Officer | Oct 8, 2026 | 11,984 | $87.32K | Oct 8, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Kazuo Kaiser Peter Officer | Oct 2, 2026 | 9,990 | $70.46K | Oct 2, 2026 | Restricted Stock Vesting Under a Registered Plan |
| S. Heier Jeffrey Officer | Oct 2, 2026 | 10,869 | $76.64K | Oct 2, 2026 | Restricted Stock Vesting Under a Registered Plan |
| D. Notman Donald Jr. Officer | Aug 31, 2026 | 1,099 | $11.25K | Aug 31, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Nayak Sanjay Officer | Aug 24, 2026 | 1,897 | $20.45K | Aug 24, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Dugel Pravin Officer | Aug 24, 2026 | 21,649 | $233.19K | Aug 24, 2026 | Restricted Stock Vesting Under a Registered Plan |
| S. Heier Jeffrey Officer | Aug 24, 2026 | 3,296 | $35.53K | Aug 24, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Kazuo Kaiser Peter Officer | Aug 24, 2026 | 3,035 | $32.70K | Aug 24, 2026 | Restricted Stock Vesting Under a Registered Plan |
| K. Waheed Nadia Officer | Jun 3, 2026 | 14,828 | $122.65K | Jun 3, 2026 | Restricted stock vesting under a registered plan |
| S. Heier Jeffrey Officer | May 26, 2026 | 3,018 | $24.75K | May 26, 2026 | Restricted stock vesting under a registered plan |
| Dugel Pravin Officer | May 26, 2026 | 21,156 | $173.51K | May 26, 2026 | Restricted stock vesting under a registered plan |
| Nayak Sanjay Officer | May 26, 2026 | 1,858 | $15.24K | May 26, 2026 | Restricted stock vesting under a registered plan |
| Kazuo Kaiser Peter Officer | May 26, 2026 | 2,967 | $24.33K | May 26, 2026 | Restricted stock vesting under a registered plan |
| Nayak Sanjay Officer | Feb 23, 2026 | 1,759 | $14.56K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| S. Heier Jeffrey Officer | Feb 23, 2026 | 3,057 | $25.30K | Feb 23, 2026 | Restricted stock vesting under a registered plan |